Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center.

Between 3 months and 1 year all parameters remained either unchanged or even showed a trend of worsening towards baseline values (Table 2 ).

also in 53,322 other papers

Discussion Our efficacy data showed that macitentan had highly significant beneficial effects regarding echo parameters, BNP levels, and NYHA class at 3 months follow-up.

also in 132,142 other papers

However, for the entire cohort, these effects persisted only for PAAT, VTI, and BNP levels over the 1-year observational period, whereas improvements of the remaining parameters persisted but failed to reach statistical significance.

also in 6,035 other papers

In the non-CHD group, there was significant reduction from baseline (24; 12–35) to 3 months (22; 12–35, p = 0.01), whereas after 1 year reduction did not reach statistical significance (22; 13–42).

also in 111,027 other papers